Insilico Medicine announced Science MMAI Gym, a domain‑specific training infrastructure to fine‑tune large language models for drug discovery tasks such as DMPK and toxicity prediction. The company frames the gym as a repeatable curriculum and benchmarking environment to convert general‑purpose LLMs into pharmaceutical‑grade scientific engines. In parallel, Insilico signed a near‑$120 million collaboration with Qilu Pharmaceutical to discover cardiometabolic candidates, extending the company’s commercial dealmaking this month. The collaboration pairs Insilico’s AI‑driven design capabilities with Qilu’s development resources. Together, the product launch and partnership highlight the industry’s push to industrialize AI for actionable preclinical outputs while monetizing model training and discovery services through sizeable pharma collaborations.